What is Biofidelity?
Founded in 2019, Biofidelity operates at the intersection of biotechnology and clinical diagnostics. The company has developed a proprietary platform designed to provide oncologists with clinically actionable data, facilitating the precise selection of cancer therapies. Unlike traditional, resource-intensive diagnostic methods, Biofidelity's technology is engineered for affordability and seamless integration into existing laboratory workflows. By democratizing access to advanced molecular markers, the firm is effectively lowering the barriers to personalized medicine, allowing for more frequent and accurate patient monitoring throughout the treatment lifecycle. Its market position is defined by its ability to transform complex molecular biology into fast, easy-to-interpret results, thereby enhancing the standard of care for cancer patients globally.
How much funding has Biofidelity raised?
Biofidelity has raised a total of $66.5M across 3 funding rounds:
Unspecified
$6.5M
Series A
$36M
Other Financing Round
$24M
Unspecified (2017): $6.5M with participation from Longwall Ventures
Series A (2022): $36M led by BlueYard Capital, Agilent Technologies, and Longwall Ventures
Other Financing Round (2024): $24M supported by Octopus Ventures, Longwall Ventures, BlueYard Capital, and Agilent Technologies
Key Investors in Biofidelity
Octopus Ventures
A founder-focused venture capital firm that backs mission-driven companies across software, health, and financial technology, providing long-term capital and strategic guidance.
Longwall Ventures
An early-stage deeptech investor specializing in leveraging UK-based scientific R&D to address global challenges through innovative, high-impact technological solutions.
BlueYard Capital
A venture capital firm focused on transformative technologies in biology, computation, and engineering, supporting visionary founders from pre-seed through Series A stages.
What's next for Biofidelity?
With the infusion of this latest capital, Biofidelity is well-positioned to accelerate its commercialization strategy and deepen its penetration into international markets. The strategic focus will likely shift toward expanding the clinical utility of its platform, potentially broadening the scope of detectable markers and strengthening partnerships with major diagnostic infrastructure providers. As the company moves beyond its initial scaling phase, the emphasis will remain on maintaining the high sensitivity of its assays while optimizing for high-throughput environments. This trajectory suggests a long-term objective of becoming a foundational element in the global oncology diagnostic ecosystem, ultimately driving better patient outcomes through improved diagnostic precision and accessibility.
See full Biofidelity company page
